
<DOC>
<DOCNO>WT02-B25-98</DOCNO>
<DOCOLDNO>IA008-000083-B004-246</DOCOLDNO>
<DOCHDR>
http://www.nami.org:80/medicat/zyprexa.htm 38.250.129.71 19970222101729 text/html 7069
HTTP/1.0 200 OK
Date: Sat, 22 Feb 1997 10:15:57 GMT
Server: Apache/1.0.5
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">
<html>

<head>
<meta http-equiv="Content-Type"
content="text/html; charset=iso-8859-1">
<meta name="keywords" content="NAMI,zyprexa">
<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Facts about Zyprexa(r) (olanzapine), 15 Oct 96</title>
</head>

<body>
<body background="/graphics/doc.gif" bgcolor="#FFFFFF" text="#000000" link="#000080" vlink="#0000FF" alink="#0000FF">
<!-- NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI -->
<!-- NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI -->
<!-- NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI NAMI -->
<a href="/index.html" target="_top"><h2 align=center><font color="#000080"><strong>N</strong><font size=3><strong>ational</strong></font><strong> A</strong><font size=3><strong>lliance</strong></font><strong> </strong><font size=3><strong>for the</strong></font><strong> M</strong><font size=3><strong>entally</strong></font><strong> I</strong><font size=3><strong>ll</strong></font></font></h2>

</a>




<h3 align="center">Medication Fact Sheet</h3>

<h3 align="center"><font color="#000080"><b>Facts about Zyprexa®
(olanzapine)--Treatment for</b></font> <a
href="../../../../helpline/schizo.htm"><font color="#000080">Schizophrenia</font></a></h3>

<table border="0" cellpadding="15" cellspacing="15" width="100%">
    <tr>
        <td valign="top" width="50%"><h4><font color="#FF0000">What
        is Zyprexa® (olanzapine)?</font> </h4>
        <p>Zyprexa<sup>®</sup> is manufactured by Eli Lilly and Company.
        It is a new &quot;atypical&quot; antipsychotic medication
        that received FDA approval for the treatment of schizophrenia
        in September 1996.</p>
        <h4><font color="#FF0000">How does Zyprexa® work?</font> </h4>
        <p>Research and clinical psychopharmacologists do not
        fully know what causes schizophrenia. It is known, however,
        that several neurotransmitters in the brain are altered
        in persons with schizophrenia. Zyprexa<sup>®</sup> works
        to reduce symptoms of schizophrenia by blocking various
        serotonin and dopamine receptors. It blocks the serotonin
        (5-HT@A) receptor more potently than the dopamine (D2) receptor.
        In animal studies, Zyprexa<sup>®</sup> is more potent at
        blocking serotonin and dopamine than Clozaril<sup>®.</sup> </p>
        <p>Animal and human studies, however, indicate that
        Zyprexa<sup>®</sup> may have a greater risk of causing
        extrapyramidal side effects than Clozaril<sup>®</sup>.
        Extrapyramidal side effects include slowing of voluntary
        movement, expressionless face, rigidity and tremor of arms
        and head, abnormal toxicity of muscle tissues, and
        restlessness.</p>
        <h4><font color="#FF0000">What is the standard dose of
        Zyprexa®?</font> </h4>
        <ol>
            <li>Oral doses of 10 mg. daily have been effective
                for most patients in the treatment of
                schizophrenia. Zyprexa<sup>®</sup> can be dosed
                once a day at bedtime.</li>
            <li>Zyprexa<sup>®</sup> is available by prescription from
                your pharmacy in 5.0 mg, 7.5 mg and 10 mg
                tablets. </li>
            <li>10 mg has been an effective starting dose in most
                patients.</li>
        </ol>
        <h4><font color="#FF0000">How is Zyprexa® different from Clozaril®?</font> </h4>
        <p>Zyprexa<sup>®</sup> differs from Clozaril<sup>®</sup>
        in side effects. Zyprexa<sup>®</sup> does not cause
        seizures of agranulocytosis, a serious deficiency of a
        type of white blood cells that could be fatal. Although
        Clozaril<sup>®</sup> works very well to treat
        schizophrenia, it requires a weekly blood draw and weekly
        prescription refills because of the monitoring for angranulocytosis.
        Weekly blood drawing and refills are not necessary with
        Zyprexa<sup>®</sup>. </p>
        <p>Zyprexa<sup>®</sup> also differs from Clozaril<sup>®</sup>
        in that it does not cause excessive drooling. Zyprexa<sup>®</sup>
        has not been directly compared to Clozaril<sup>®</sup>
        in clinical studies in patients, so it is not now known
        which drug will be better for certain patients with schizophrenia. </p>
        </td>
        <td valign="top" width="50%"><h4><font color="#FF0000">Are
        there other new drugs available to treat schizophrenia?</font> </h4>
        <ol>
            <li>pending FDA approval is sertindol (Serlect<sup>®).</sup> </li>
            <li>Risperdal<sup>®</sup> </li>
            <li>Clozaril<sup>®</sup> </li>
        </ol>
        <h4><font color="#FF0000">Possible Side Effects</font> </h4>
        <ol>
            <li>weight gain</li>
            <li>tiredness</li>
            <li>fatigue, stiff body movement, and blurred vision. </li>
            <li>Zyprexa<sup>®</sup> does not cause as much blurred
                vision or dryness of the mouth, or as frequent
                stiff body movements. </li>
        </ol>
        <h4><font color="#FF0000">How is Zyprexa® different from Risperdal®?</font> </h4>
        <p>There have been no direct clinical comparisons between
        Zyprexa<sup>®</sup> and Risperdal<sup>®.</sup> Eli
        Lilly and Company is currently conducting such a study,
        however. This study is an international effort, and results
        may be available in the next year. </p>
        <h4><font color="#FF0000">How will Zyprexa® be
        administered?</font> </h4>
        <p>Zyprexa<sup>®</sup> is available from your pharmacy as
        oral tablets. The strengths available are 5 mg, 7.5 mg
        and 10 mg tablets. The drug is to be taken by mouth. </p>
        <p>&nbsp;</p>
        <p>&nbsp;</p>
        <p>&nbsp;</p>
        <p><font color="#0000FF"><strong><i>Reviewed by Dale
        Grothe, Pharm D., National Institute of Mental Health,
        and David Daniel, MD, Arlington, VA November 1996</i></strong></font></p>
        <p>&nbsp;</p>
        <p>&nbsp; </p>
        <p>&nbsp; </p>
        <h3><em>FOR MORE INFORMATION ABOUT BRAIN DISORDERS (MENTAL
        ILLNESSES), CONTACT THE NATIONAL ALLIANCE FOR THE MENTALLY
        ILL AT 1-800-950-NAMI.</em> </h3>
        </td>
    </tr>
</table>
<hr><h6>
<p align=center><a href="/poc.htm">CONTACT</a> | <a href="/joinform.htm">MEMBERSHIP</a> | <a href="mailto:barbara@nami.org">WEBMASTER</a></p></h6>
<P><P>
<center><H6>Copyright &copy 1996 <a href="/index.html" target=_top>National Alliance for the Mentally Ill</a> - All Rights Reserved</H6>
</center></body>













































































</body>
</html>
</DOC>